前列腺癌中的前列腺特异性膜抗原PET显像:机遇与挑战
本文为系统综述,描述PSMA靶向PET示踪剂的特征及其在前列腺癌患者中的临床应用。多数PSMA PET研究集中于生化复发患者,其在前列腺癌原发分期、治疗计划、疗效评估及PSMA放射配体治疗中的附加价值也有探索。PSMA PET有望改善患者管理,但诊断改善对总生存的影响尚无答案,尚需前瞻性多中心试验验证其有效性和实用性。
要点
- PSMA靶向PET示踪剂可按正电子发射体及靶向策略分类。
- 多数PSMA PET研究聚焦生化复发前列腺癌患者。
- PSMA PET在原发分期、治疗计划、疗效评估及放射配体治疗中的价值也有研究。
核心结论
- PSMA PET有望改善前列腺癌患者管理,但诊断改善对总生存的影响仍无答案。
- PSMA PET临床推广仍面临诸多挑战,现阶段需要前瞻性多中心试验验证其有效性和实用性。
研究设计与样本
- 系统综述,描述PSMA靶向PET示踪剂的特征及其在前列腺癌患者中的临床应用。
局限性
- 诊断改善对总生存的影响仍无答案。
- PSMA PET临床推广仍面临诸多挑战。
- 现阶段需要前瞻性多中心试验验证PSMA PET的有效性和实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The aim of this systematic review was to describe the characteristics of prostate-specific membrane antigen (PSMA)-targeting PET and their clinical applications in prostate cancer patients. There have been major strides in the design, synthesis of PSMA-targeting PET tracers over the past several years. PSMA-targeting PET tracers can be categorized, according to positron emitters and targeting strategies for the PSMA. The majority of PSMA PET studies has been focused on patients with biochemical recurrence, but additional values of PSMA PET have also been investigated for use in primary staging, treatment planning, response evaluation, and PSMA radioligand therapy. PSMA PET is expected to bring improvements in the management of patients, but the impact of improved diagnosis by PSMA on overall survival remains unanswered. Many challenges still await PSMA PET to expedite the use in the clinical practice. At this early stage, prospective multicenter trials are needed to validate the effectiveness and usefulness of PSMA PET.
引用
- Oh SW, Cheon GJ. Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges. Korean J Radiol. 2018. PMID: 30174470. doi:10.3348/kjr.2018.19.5.819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。